AKANDA CORP.

AKAN ·Healthcare, Drug Manufacturers - General, United Kingdom
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $836.7K $423.7K $2.6M $41.4K $2.1K
Cost of Revenue $628.3K $364.3K $566.3K $43.0K $1.8K
Gross Profit $208.4K $59.3K $3.3M $-1.6K $-58.2K
Gross Margin 24.9% 14.0% 124.8% -3.8% -2,821.3%
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-4.4M $-3.7M $-20.2M $-2.6M $-1.7M
Operating Margin -523.8% -863.6% -770.2% -6,203.4% -80,781.0%
Interest Expense $14.6K
Pretax Income
Income Tax Expense
Net Income $-4.1M $-32.3M $-11.7M $-8.1M $-2.3M
Net Margin -489.6% -7,617.7% -445.0% -19,625.9% -111,569.9%
EPS (Basic) $-3.93 $-573.11 $-3.86 $-0.50 $-0.18
EPS (Diluted) $-3.93 $-573.11 $-3.86 $-0.50 $-0.18
Shares Outstanding (Basic) 2.0M 5.6M 34.6M
Shares Outstanding (Diluted) 2.0M 5.6M 34.6M
Dividends Per Share